



Published in final edited form as:

Biol Blood Marrow Transplant. 2019 May ; 25(5): e145–e154. doi:10.1016/j.bbmt.2018.11.033.

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Yoshihiro Inamoto^{#1}, Igor Petri ek^{#2}, Linda Burns³, Saurabh Chhabra⁴, Zack DeFilipp⁵, Peiman Hematti⁶, Alicia Rovó⁷, Raquel Schears⁸, Ami Shah⁹, Vaibhav Agrawal¹⁰, Aisha Ahmed¹¹, Ibrahim Ahmed¹², Asim Ali¹³, Mahmoud Aljurf¹⁴, Hassan Alkhateeb⁸, Amer Beitinjaneh¹⁵, Neel Bhatt¹⁶, Dave Buchbinder¹⁷, Michael Byrne¹⁸, Natalie Callander¹⁹, Kristina Fahnehjelm^{20,21}, Noshah Farhadfar²², Robert Peter Gale²³, Siddhartha Ganguly²⁴, Gerhard C. Hildebrandt²⁵, Erich Horn²², Ann Jakubowski²⁶, Rammurti T. Kamble²⁷, Jason Law²⁸, Catherine Lee²⁹, Sunita Nathan³⁰, Olaf Penack³¹, Ravi Pingali³², Pinki Prasad³³, Drazen Pulanic^{34,35,36}, Seth Rotz³⁷, Aditya Shreenivas³⁸, Amir Steinberg³⁸, Khalid Tabbara³⁹, André Tichelli⁴⁰, Baldeep Wirk⁴¹, Jean Yared⁴², Grzegorz W. Basak⁴³, Minoo Battiwalla⁴⁴, Rafael Duarte⁴⁵, Bipin N. Savani⁴⁶, Mary ED Flowers⁴⁷, Bronwen E Shaw¹⁶, and Nuria Valdés-Sanz^{#48}

¹Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan ²Department of Ophthalmology, University Clinical Hospital Zagreb, Zagreb, Croatia ³CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN ⁴Medical College of Wisconsin, Milwaukee, WI ⁵Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA ⁶Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI ⁷Universitätsspital Bern, Bern, Switzerland ⁸Mayo Clinic Rochester, Rochester, MN ⁹Division of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford School of Medicine, Palo Alto, CA ¹⁰Indiana University Simon Cancer Center, Indianapolis, IN ¹¹University of California, San Francisco, CA ¹²Department of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, MO ¹³St. Louis Medical Clinic, St. Louis, MO ¹⁴Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia ¹⁵University of Miami, Miami, FL ¹⁶CIBMTR (Center for International Blood and Marrow Transplant Program), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI ¹⁷Division of Pediatrics Hematology, Children's Hospital of Orange County, Orange, CA

Correspondence and reprint requests: Yoshihiro Inamoto, MD, PhD, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo, Tokyo, Japan 104-0045; Phone: +81-3-3547-5201; FAX: +81-3-3542-3815; yinamoto@ncc.go.jp.

Conflict-of-interest statement: There are no conflicts of interest to disclose.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

¹⁸Vanderbilt University Medical Center, Nashville, TN ¹⁹University of Wisconsin Carbone Cancer Center, Madison, WI ²⁰Department of Clinical Neuroscience, Karolinska Institutet, St. Erik Eye Hospital, Stockholm, Sweden ²¹Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden ²²Shands Healthcare & University of Florida, Gainesville, FL ²³Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom ²⁴Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS ²⁵Markey Cancer Center, University of Kentucky, Lexington, KY ²⁶Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY ²⁷Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX ²⁸Tufts Medical Center, Boston, MA ²⁹Utah Blood and Marrow Transplant Program Huntsman Cancer Institute, University of Utah, Salt Lake City, UT ³⁰Rush University Medical Center, Chicago, IL ³¹Dept. of Internal Medicine, Div. Haematology & Oncology, Charite University Medicine, Campus Rudolf Virchow, Berlin ³²Houston Methodist Hospital, Houston, TX ³³Children's Hospital, New Orleans, LA ³⁴Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia ³⁵University of Zagreb, School of Medicine, Zagreb, Croatia ³⁶J. J. Strossmayer University of Osijek, Faculty of Medicine Osijek, Osijek, Croatia ³⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH ³⁸Division of Hematology and Oncology, Mount Sinai Hospital, New York, NY ³⁹The Wilmer Ophthalmological Institute of The Johns Hopkins University, School of Medicine, Baltimore, MD ⁴⁰University Hospital Basel, Basel, Switzerland ⁴¹Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA ⁴²Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD ⁴³Medical University of Warsaw, Warsaw, Poland ⁴⁴Hematology Branch, Sarah Cannon BMT Program, Nashville, TN ⁴⁵University Hospital Puerta de Hierro, Madrid, Spain ⁴⁶Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN ⁴⁷Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA ⁴⁸Department of Ophthalmology, Hospital Universitario Puerta de Hierro, Madrid, Spain

These authors contributed equally to this work.

Abstract

Non-graft-versus-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complications and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who

undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.

Keywords

hematopoietic cell transplantation; complication; eye; review; prevention; treatment

Introduction

Hematopoietic cell transplantation (HCT) is a curative treatment for many hematologic malignancies and nonmalignant disorders, although a variety of complications and late effects may occur.¹⁻³ Non-graft-versus-host disease (non-GVHD) ocular complications are generally uncommon after HCT, but can cause prolonged morbidity affecting activities of daily living and quality of life. It is important for all health professionals taking care of HCT recipients to have adequate knowledge about ocular complications.

This review summarizes recent updates in non-GVHD ocular complications after HCT in a collaborative effort between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation (EBMT). We aim to provide an expert review of non-GVHD ocular complications after HCT with evidence-based recommendations for clinical practice and future research. The most frequent ocular complication after allogeneic HCT is ocular GVHD, which is addressed in a companion review.

Structures of the eye are shown in Figure 1. The anterior segment of the eye is formed by the cornea, aqueous humor, iris, ciliary body and crystalline lens. The posterior segment is formed by the vitreous body, retina, choroid and optic nerve.

Methods

We searched the Medline (PubMed) database using a broad search strategy to identify studies related to ocular complications after HCT. The primary search was conducted using the terms “hematopoietic transplantation AND (eye OR ocular),” and 552 articles were identified as of March 31, 2018. Relevant articles were also reviewed as needed. Recommendations are organized according to an evidence-based system described previously⁴ to reflect the strength of recommendations and the quality of evidence supporting them (Table 1).

Cataracts

Incidence and risk factors

Cataracts, defined clinically as progressive opacification of the lens, are one of the most frequent late ocular complications after HCT. The reported incidence of cataracts in HCT survivors varies among studies, ranging from 11% to 100% in adults^{5, 6} and from 4% to 76% in children (supplementary Table S1).^{7, 8} This large variability is attributable to heterogeneity in patient populations, conditioning regimens, supportive care, and length of follow-up.

Among patients who undergo allogeneic HCT, total body irradiation (TBI) as part of the conditioning regimen has been identified as a major risk factor for cataract formation. Posterior subcapsular cataracts are the most common subtype associated with exposure to ionizing radiation. The risk of cataracts is much higher after single dose TBI compared to hyper-fractionated TBI.⁹ A higher dose rate (>0.04 Gy/min) has also been identified as a risk factor.¹⁰ Lens-shielding in patients receiving TBI has been tested, mostly in pediatric patients, and has shown to reduce the incidence and severity of cataracts,¹¹ although controversy exists regarding a potentially increased risk of extramedullary disease relapse in the shielded area. One pediatric study showed that fractionated TBI was associated with cataracts requiring surgery, while chemotherapy-based conditioning caused less severe cataracts usually not requiring surgery.¹²

In addition to TBI, prolonged steroid therapy, such as for treatment of GVHD, has been identified as an independent risk factor for cataracts after HCT.^{13, 14} A population-based study showed that even inhaled corticosteroids were associated with the development of posterior subcapsular and nuclear cataracts.¹⁵ Survivors of allogeneic HCT are more likely to develop cataracts, when compared with those of autologous HCT.¹⁰

Screening, prevention and treatment

Comprehensive evaluation by ophthalmologists before HCT and then annually after HCT is warranted to diagnose and determine the appropriate timing for surgical intervention of cataracts (supplementary Table S2).¹⁶ In adults, decreased visual acuity reported by the patients should initiate an eye examination. Pediatric patients require regular follow-up given that they may not complain of visual changes. Cataract prevention with use of fractionated TBI or use of non-TBI conditioning regimens and corticosteroids sparing, when clinically feasible, is the most important for minimizing cataract development.^{9, 12}

Surgery is the standard treatment for cataracts. Early diagnosis and appropriate timing for surgery are important in young children, especially those under 7 years old, in order to prevent irreversible amblyopia.¹⁷ Cataract surgery is usually indicated for those with bilateral cataracts and best corrected visual acuity of 20/40 or worse, although the visual threshold for performing surgery should be tailored according to the needs of the patient. In both adult and pediatric patients, cataracts may present with dry eye and other manifestations of ocular GVHD. The concurrent ocular surface problems and postoperative complications should be controlled to obtain good surgical outcomes in these patients.¹⁸

Ocular infections

Ocular infections can be severe after HCT. The types of infectious organisms, involved ocular structures, symptoms and diagnostic tests are summarized in Table 2.

Incidence and risk factors

The incidence of ocular infections has decreased over time with advances in prophylaxis, screening guidelines and effective medications.^{19, 20} In a large series of 620 patients undergoing allogeneic HCT, 18 (3%) had serious ocular infections due to Gram-positive and negative bacteria (1.6%), fungi (0.16%), and virus (0.8%).²¹ *Candida* and *Aspergillus* species are the most frequently isolated organisms in fungal keratitis and endophthalmitis.²² The most common ocular protozoan infection is *Toxoplasma gondii*, although ocular toxoplasmosis is rare (0.3-0.5% of autologous and allogeneic HCT recipients).^{23, 24} Viruses that cause ocular infection after HCT include cytomegalovirus (CMV),²⁵⁻²⁸ herpes simplex virus (HSV),²⁹ varicella zoster virus (VZV),^{30, 31} and adenovirus (ADV).³² The most common virus that affects the eyes is CMV, with the incidence of retinitis ranging from <1% to 5% in all HCT recipients, and from 5% to 23% in patients with CMV viremia.²⁵⁻²⁸ Ocular infections by HSV, VZV and ADV are rare.²⁹⁻³¹ In one study, ocular infection accounted for 2% of all VZV infections.³⁰

Since ocular infections are uncommon, risk factors are often extrapolated from those for infections at other sites and include pre-HCT latent infections and post-HCT neutropenia, impaired cellular and humoral immunity and development of GVHD (Figure 2).^{19, 21} Patients with neutropenia or humoral deficiency are susceptible to developing bacterial infections, including corneal ulcers and periorbital cellulitis.²¹ Risk factors for ocular fungal infection include fungemia and immunosuppression.³³ Risk factors for ocular toxoplasmosis include toxoplasma infection before HCT and impaired cellular immunity.²³ Risk factors for viral infections include positive serostatus before HCT, history of viremia before HCT, low lymphocyte counts, chronic GVHD, HLA mismatching, and unrelated donor.^{25-27, 30} Candidates for HCT should undergo serologic testing for latent viral infections and toxoplasmosis.^{19, 20}

Screening, prevention and treatment

Eye examination should be performed before HCT and at any time when patients have ocular symptoms after HCT. Early detection and prompt treatment are required to prevent visual loss. Prevention and treatment of ocular infections is similar to that of other systemic infections except where ocular penetration of the therapeutic agent is poor.

Bacterial infections are treated with intravenous antibiotics based on culture and sensitivity results. Topical antibiotics are also used for bacterial keratitis.³⁴ Oral or intravenous antifungal therapy is considered for patients with ocular fungal infection depending on the causative pathogen. Intravitreal administration can be performed with most antifungal agents, including amphotericin B, echinocandins and azoles, as penetration into eyes may not be sufficient with intravenous administration.³⁵ To treat fungal keratitis, antifungal agents such as voriconazole can be used topically.³⁶ There are no randomized trials

comparing the efficacy of different prophylactic agents to prevent toxoplasmosis after HCT, although observational studies have demonstrated efficacy of oral trimethoprim-sulfamethoxazole from engraftment until immunosuppressive therapy is discontinued.³⁷ Treatment of active toxoplasmosis consists of oral antimicrobial agents such as trimethoprim-sulfamethoxazole, pyrimethamine/sulfadiazine, clindamycin, atovaquone, or azithromycin.³⁸

Systemic therapy (e.g. intravenous ganciclovir, oral valganciclovir and intravenous foscarnet) should be used for treatment of CMV ocular diseases.²⁸ When patients do not respond sufficiently to systemic therapy, intravitreal therapy is considered.²⁸ Third-party donor-derived CMV pp65-specific T-cells have resulted in resolution of refractory CMV retinitis.³⁹ Prophylactic oral acyclovir has reduced the risk of HSV infection.⁴⁰ A combination of systemic therapy and topical therapies is recommended for treatment of HSV ocular infection. Intravenous cidofovir is recommended for treatment of ADV infection.⁴¹

Ocular involvement by malignancy

Incidence and diagnosis

There is very limited information regarding ocular manifestations of malignancy after HCT. The incidence of ocular involvement by malignancy is rare. Relapsed disease after HCT may involve eyes, either *de novo* or in association with central nervous system or systemic relapse.^{42, 43}

Clinical presentations of intraocular neoplasms after HCT can include the anterior and posterior segments and orbital manifestations, amongst others. Despite the infrequent incidence of *de novo* or recurrent ocular neoplasms, a high index of suspicion necessitates proper clinical assessment and evaluation by an experienced ophthalmologist.⁴⁴ Computed tomography or magnetic resonance imaging may be helpful. Cytology, immunohistochemistry, flow cytometry, cytogenetics and molecular studies on aspirated fluid or tissue biopsy are necessary for definitive diagnosis.⁴⁴⁻⁴⁶

Screening, prevention and treatment

No evidence is available for screening and prevention of malignancies with ocular involvement. As a general recommendation, ocular evaluation may be necessary in patients with relapsed primary disease and ocular symptoms, in those with previous ocular involvement, and in those with new malignancy involving the central nervous system. Treatment approaches are extrapolated from literature on treatment of intraocular neoplasms in general and are not validated in HCT settings. These include intravitreal chemotherapy, radiation, photodynamic laser therapy, and disease-specific interventions based on site and histology of neoplasm.⁴⁷⁻⁴⁹

Ischemic microvascular retinopathy

Incidence and risk factors

Ischemic microvascular retinopathy (IMR) after HCT is a complication of the posterior segment that was first described in 1983.⁵⁰ IMR presents with retinal cotton-wool patches, vitreous hemorrhage and optic disc edema. The clinical presentation varies from asymptomatic to sight-threatening forms. Symptomatic patients often complain of blurred vision or color vision abnormality which can occur abruptly, gradually or progressively. One or both eyes can be affected.

There are at least 8 cohort studies examining complications of the posterior segment after HCT (supplementary Table S3).^{21, 22, 51-56} IMR has been reported after both autologous and allogeneic HCT, and the incidence of IMR ranges from 0% to 10%,^{21, 22, 51-56} although the incidence is likely to be underestimated due to the asymptomatic presentation in many patients. IMR usually occurs within 6 months of allogeneic HCT,⁵² although atypically late onset around 50 months after allogeneic HCT has been described in 4 patients.⁵⁴ Potential risk factors for IMR include TBI conditioning,^{22, 52, 54} cyclosporine prophylaxis,^{22, 52} and conditioning regimens including busulfan or carmustine.^{53, 54}

Pathogenesis

Although the pathogenesis of HCT-associated IMR has not yet been elucidated, multifactorial processes are likely to cause capillary damage in the ocular fundus. IMR after HCT is morphologically similar to fundus changes associated with malignant hypertension in the general population,⁵⁷ but most HCT patients with IMR do not have malignant hypertension, suggesting a different pathogenesis. Although radiation has been associated with vascular retinopathy,⁵⁸ IMR also occurs among adult patients who have had autologous HCT using non-TBI conditioning regimens.⁵³ In an experimental rat model using retinal imaging, the combination of cyclosporine and dexamethasone led to progressive degenerative changes of the fundus with histologic thinning of the outer nuclear layer of the retina, suggesting that calcineurin inhibitors may contribute to ocular vascular endothelial injury.⁵⁹

Screening, prevention and treatment

Data are lacking for the management of IMR after HCT. Based on the potential risk factors, it is important to avoid radiation to ocular areas, to monitor levels of calcineurin inhibitors, and to treat cardiovascular risk factors such as hypertension, diabetes, and hyperlipidemia. Importantly, spontaneous regression is frequent and permanent loss of visual acuity is rare. Withdrawal or reduction of immunosuppression can lead to resolution of the retinal lesions in many cases,⁶⁰ although proliferative retinopathy may have a poor visual prognosis.⁶¹

Future research should focus on the biology of IMR and identification of risk factors. Novel findings in retinopathy due to diabetes and sickle cell disease are worth investigating in HCT patients with IMR. For example, new sensitive technologies of ultra-wide field fluorescein angiography, spectral-domain optical coherence tomography and optical coherence tomography angiography may help diagnosis.^{62, 63} Vascular endothelial growth factor

(VEGF) may serve as a diagnostic biomarker and a treatment target, since tissue ischemia increases VEGF that can promote abnormal neovascularization.⁶⁴

Other ocular complications

Glaucoma

Glaucoma was diagnosed in 1.7% of HCT survivors, but this frequency was similar to 1.9% in their siblings.⁶⁵ In a study of 218 patients with chronic GVHD, 33 (15%) had increased intraocular pressure, 8 (3.6%) had suspicion of glaucoma, and 1 (0.4%) had glaucoma.⁶⁶ Classically, glaucoma is known as a late complication of irradiation used in conditioning regimens, with a median interval of 22 months to onset of glaucoma.⁶⁷ Long-term use of systemic corticosteroids for chronic GVHD can elevate intraocular pressure in susceptible patients.^{66, 68, 69} The risk of early intraocular pressure rise and amount of elevation are greater in children than adults.⁷⁰ Intraocular pressure may be elevated even after topical steroid use such as eye drops, ointment and inhalation. No correlation has been demonstrated between stem cell source and glaucoma.²¹

Patients who are receiving systemic or topical steroids should have periodic monitoring of intraocular pressure. A rise in intraocular pressure is often transient and resolves within 4 weeks of tapering or cessation of systemic steroid therapy.⁶⁶ If steroid use exceeds 18 months, the intraocular pressure may be permanently elevated. First-line treatment of glaucoma is topical aqueous humor suppressants, including beta-blockers, alpha 2 agonists, or carbonic anhydrase inhibitors.^{71, 72} For the 1-5% of patients with intractable glaucoma not adequately responsive to eye drop treatment, glaucoma surgery with trabeculectomy or other technique may be necessary to prevent vision loss.⁷³ Laser trabeculoplasty has shown efficacy in small retrospective studies.⁷⁴

Central retinal vein occlusion (CRVO)

CRVO is a vision-threatening retinal vascular disease, with an incidence of 0.2%-0.4% in the general population.⁷⁵ The pathophysiology of CRVO is not yet fully understood, but systemic diseases including hypertension, hyperlipidemia and diabetes mellitus, hypercoagulability and hyperviscosity may be associated with its pathophysiology. There are several reports of CRVO in patients with hematologic malignancies, but only two cases of CRVO have been reported at 2 and 5 months after HCT.⁷⁶

The central retinal vein is compressed in patients with CRVO by the adjacent central retinal artery at the lamina cribrosa, leading to increased venous and capillary pressures, endothelial damage, permeability changes, and extravasation of blood and serous fluid in the retina. Capillary perfusion is reduced due to increased interstitial pressures, causing tissue ischemia. Interleukin-6 and VEGF are secreted in response to the ischemia, which promotes retinal edema, neovascularization and other complications including vitreous hemorrhage, tractional retinal detachment, iris neovascularization and neovascular glaucoma.⁷⁷

Intravitreal injections of anti-VEGF agents are the first-line treatment for symptomatic macular edema due to CRVO, and have shown significant reduction in central retinal thickness from macular edema, significant improvement in best corrected visual acuity and a

delay in development of neovascular complications in randomized studies.^{78, 79} Intravitreal steroid injections also have improved macular edema after CRVO in a randomized study.⁸⁰ A retrospective study showed that macular grid and panretinal laser photocoagulation are also effective for CRVO,⁸¹ and these treatments are considered as second line or in cases with extensively ischemic retina.

Retinal hemorrhage and retinal detachment

Retinal hemorrhage and detachment usually occur as a consequence of other pathologies such as CMV retinitis and neovascularization due to ischemic retinopathy. A retrospective study of 635 patients who had allogeneic HCT showed that the most common posterior segment complication after allogeneic HCT was retinal hemorrhage (3.2%).⁷⁶ Standard treatments include platelet transfusion to maintain the platelet count over 50,000/ μ l and correction of coagulopathy.

Retinal detachment is a rare posterior segment complication and accounts for <1% of ocular complications after HCT.^{22, 76} It can be seen in chronic GVHD, CMV retinitis, and rarely in acute GVHD. Most of the cases manifest as rhegmatogenous retinal detachment,^{76, 82} but 2 cases of vision-threatening exudative bullous retinal detachment have been reported in the literature.⁸³ Tractional retinal detachment due to proliferative retinopathy has also been reported after HCT.⁸⁴ In one study, retinal detachment occurred in 13% patients with CMV retinitis, and the visual prognosis was often poor.⁷⁶ Treatment depends on underlying disease and includes laser photocoagulation, cryotherapy, and various surgical techniques.

Medications with ocular toxicities

A variety of medications can cause ocular toxicities after HCT (Table 3). The most commonly reported ocular toxicity of anti-cancer drugs is keratoconjunctivitis. Systemic corticosteroids accelerate cataract formation^{13, 14, 85} and glaucoma development.⁶⁶ Topical corticosteroids are commonly used for treatment of ocular GVHD, but their long-term use is associated with elevated intraocular pressure, decreased epithelial healing, infection and cataracts.¹⁸ High-potency steroid eye drops should be avoided, and intraocular pressure should be monitored in patients who continue steroid eye drops for more than 2 weeks.⁶⁶ Topical use of tacrolimus and cyclosporine for treatment of ocular GVHD can cause conjunctival injection, burning and stinging sensation, which may be controlled with lubricating eye drops.⁸⁶⁻⁸⁸ Oral or intravenous voriconazole can cause blurred vision, changes in visual acuity and color perception, photophobia and visual hallucinations.⁸⁹ Other medications such as oral antihistamines⁹⁰ (e.g., diphenhydramine, loratadine) and oral anticholinergics⁹¹ (e.g., sedatives, sleep aids, cold preparations, antidiarrheal and nasal decongestants) can inhibit lacrimal glandular secretions and cause dry eyes. Scopolamine patches used as antiemetic after high-dose chemotherapy can lead to anisocoria or mydriasis if the eye is contaminated with scopolamine.⁹² Oral selective serotonin reuptake inhibitors can result in reduced accommodation.⁹³ Oral antipsychotics including phenothiazines such as haloperidol, chlorpromazine and thioridazine can cause mydriasis, cycloplegia,⁹³ and pigmentation of conjunctiva, cornea, eyelids and retina with their long-term use.⁹⁴ Oral sildenafil used for erectile dysfunction after HCT can cause a blue tinge to vision or an

increased brightness of lights.⁹⁵ Topical nonsteroidal anti-inflammatory eye drops can cause stromal necrosis in dry eyes, and should be avoided in patients with ocular GVHD.⁹⁶

Summary and future recommendations

The incidence, risk factors, screening and prevention recommendations for non-GVHD ocular complications after HCT are summarized in Table 4. Treatment recommendations are summarized in Table 5. Although non-GVHD ocular complications after HCT are rare, baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up ocular evaluations should be considered according to clinical findings and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT, particularly in high-risk patients. There is significant overlap in the clinical presentation between infectious and non-infectious ocular complications and better diagnostic techniques need to be developed. There remains a paucity of data on the long-term visual outcomes, particularly in pediatric patients, as most studies have short follow up of less than 2 years. Better data collection is necessary to address these remaining questions. Both transplant physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide a comprehensive collaborative team care.

Acknowledgments

Financial disclosure: The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 4U10HL069294 from NHLBI and NCI; a contract HSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; * Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Mediware; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. - Japan; PCORI; *Pfizer, Inc.; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government.

* Corporate Members

References

1. Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. *Blood*. 2003;101:3373–85. [PubMed: 12511420]
2. Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. *Haematologica*. 2017;102:614–25. [PubMed: 28232372]
3. Battiwalla M, Hashmi S, Majhail N, Pavletic S, Savani BN, Shelburne N. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. *Biol Blood Marrow Transplant*. 2017;23:6–9. [PubMed: 27989931]

4. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. *Biol Blood Marrow Transplant*. 2006;12:375–96. [PubMed: 16545722]
5. Dunn JP, Jabs DA, Wingard J, Enger C, Vogelsang G, Santos G. Bone marrow transplantation and cataract development. *Arch Ophthalmol*. 1993;111:1367–73. [PubMed: 8216017]
6. Tichelli A, Gratwohl A, Egger T, Roth J, Prunte A, Nissen C, et al. Cataract formation after bone marrow transplantation. *Ann Intern Med*. 1993;119:1175–80. [PubMed: 8239248]
7. Kinori M, Bielora B, Souroujon D, Hutt D, Ben-Bassat Mizrachi I, Huna-Baron R. Ocular complications in children after hematopoietic stem cell transplantation without total body irradiation. *Graefes Arch Clin Exp Ophthalmol*. 2015;253:1397–402. [PubMed: 25708560]
8. Frisk P, Hagberg H, Mandahl A, Soderberg P, Lonnerholm G. Cataracts after autologous bone marrow transplantation in children. *Acta Paediatr*. 2000;89:814–9. [PubMed: 10943964]
9. Benyunes MC, Sullivan KM, Deeg HJ, Mori M, Meyer W, Fisher L, et al. Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. *Int J Radiat Oncol Biol Phys*. 1995;32:661–70. [PubMed: 7790252]
10. Belkacemi Y, Labopin M, Vernant JP, Prentice HG, Tichelli A, Schattenberg A, et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. *Int J Radiat Oncol Biol Phys*. 1998;41:659–68. [PubMed: 9635717]
11. van Kempen-Harteveld ML, van Weel-Sipman MH, Emmens C, Noordijk EM, van der Tweel I, Revesz T, et al. Eye shielding during total body irradiation for bone marrow transplantation in children transplanted for a hematological disorder: risks and benefits. *Bone Marrow Transplant*. 2003;31:1151–6. [PubMed: 12796795]
12. Fahnehjelm KT, Tornquist AL, Olsson M, Winiarski J. Visual outcome and cataract development after allogeneic stem-cell transplantation in children. *Acta Ophthalmol Scand*. 2007;85:724–33. [PubMed: 17725615]
13. van Kempen-Harteveld ML, Struikmans H, Kal HB, van der Tweel I, Mourits MP, Verdonck LF, et al. Cataract-free interval and severity of cataract after total body irradiation and bone marrow transplantation: influence of treatment parameters. *Int J Radiat Oncol Biol Phys*. 2000;48:807–15. [PubMed: 11020578]
14. Najima Y, Kakihana K, Ohashi K, Yamamoto N, Kobayashi T, Yamashita T, et al. Incidence, risk factors, and clinical outcomes of cataracts following hematopoietic stem cell transplantation. *Am J Hematol*. 2011;86:508–10. [PubMed: 21509794]
15. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. *N Engl J Med*. 1997;337:8–14. [PubMed: 9203425]
16. Bernard F, Auquier P, Herrmann I, Contet A, Poiree M, Demeocq F, et al. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study. *Bone Marrow Transplant*. 2014;49:709–16. [PubMed: 24535128]
17. Tear Fahnehjelm K, Tomquist AL, Olsson M, Backstrom I, Andersson Gronlund M, Winiarski J. Cataract after allogeneic hematopoietic stem cell transplantation in childhood. *Acta Paediatr*. 2016;105:82–9. [PubMed: 26331596]
18. de Melo Franco R, Kron-Gray MM, De la Parra-Colin P, He Y, Musch DC, Mian SI, et al. Outcomes of cataract surgery in graft-versus-host disease. *Cornea*. 2015;34:506–11. [PubMed: 25826324]
19. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant*. 2009;15:1143–238. [PubMed: 19747629]
20. Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Kruger W, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. *Ann Hematol*. 2016;95:1435–55. [PubMed: 27339055]

21. Tabbara KF, Al-Ghamdi A, Al-Mohareb F, Ayas M, Chaudhri N, Al-Sharif F, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. *Ophthalmology*. 2009; 116:1624–9. [PubMed: 19729097]
22. Coskuncan NM, Jabs DA, Dunn JP, Haller JA, Green WR, Vogelsang GB, et al. The eye in bone marrow transplantation. VI. Retinal complications. *Arch Ophthalmol*. 1994;112:372–9. [PubMed: 8129664]
23. Sumi M, Aosai F, Norose K, Takeda W, Kirihara T, Sato K, et al. Acute exacerbation of *Toxoplasma gondii* infection after hematopoietic stem cell transplantation: five case reports among 279 recipients. *Int J Hematol*. 2013;98:214–22. [PubMed: 23749548]
24. Decembrino N, Comelli A, Genco F, Vitullo A, Recupero S, Zecca M, et al. Toxoplasmosis disease in paediatric hematopoietic stem cell transplantation: do not forget it still exists. *Bone Marrow Transplant*. 2017;52:1326–9. [PubMed: 28604668]
25. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. *Clin Infect Dis*. 2001;32:214–9. [PubMed: 11170910]
26. Jeon S, Lee WK, Lee Y, Lee DG, Lee JW. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. *Ophthalmology*. 2012;119:1892–8. [PubMed: 22657564]
27. Hiwarkar P, Gajdosova E, Qasim W, Worth A, Breuer J, Chiesa R, et al. Frequent occurrence of cytomegalovirus retinitis during immune reconstitution warrants regular ophthalmic screening in high-risk pediatric allogeneic hematopoietic stem cell transplant recipients. *Clin Infect Dis*. 2014;58:1700–6. [PubMed: 24700657]
28. Laroche MB, Phan R, Craddock J, Abzug MJ, Curtis D, Robinson CC, et al. Cytomegalovirus Retinitis in Pediatric Stem Cell Transplants: Report of a Recent Cluster and the Development of a Screening Protocol. *Am J Ophthalmol*. 2017;175:8–15. [PubMed: 27746296]
29. Chen Y, Scieux C, Garrait V, Socie G, Rocha V, Molina JM, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. *Clin Infect Dis*. 2000;31:927–35. [PubMed: 11049772]
30. Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. *Biol Blood Marrow Transplant*. 2000;6:44–9. [PubMed: 10707998]
31. Walton RC, Reed KL. Herpes zoster ophthalmicus following bone marrow transplantation in children. *Bone Marrow Transplant*. 1999;23:1317–20. [PubMed: 10414922]
32. Castleton A, Kottaridis PD. A case of 'red eye' post allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2007;39:241–2. [PubMed: 17211428]
33. Donahue SP, Greven CM, Zuravleff JJ, Eller AW, Nguyen MH, Peacock JE Jr., et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. *Ophthalmology*. 1994;101:1302–9. [PubMed: 8035995]
34. Shah VM, Tandon R, Satpathy G, Nayak N, Chawla B, Agarwal T, et al. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers. *Cornea*. 2010;29:751–7. [PubMed: 20489580]
35. Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous *Aspergillus* endophthalmitis. *Ophthalmology*. 2006;113:1184–6. [PubMed: 16713628]
36. Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. *JAMA Ophthalmol*. 2013;131:422–9. [PubMed: 23710492]
37. Martino R, Bretagne S, Einsele H, Maertens J, Ullmann AJ, Parody R, et al. Early detection of *Toxoplasma* infection by molecular monitoring of *Toxoplasma gondii* in peripheral blood samples after allogeneic stem cell transplantation. *Clin Infect Dis*. 2005;40:67–78. [PubMed: 15614694]
38. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, van Ruyven RL, Klok AM, Hoyng CB, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and

- sulfadiazine for the treatment of ocular toxoplasmosis. *Am J Ophthalmol.* 2002;134:34–40. [PubMed: 12095805]
39. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. *Blood.* 2013;121:5113–23. [PubMed: 23610374]
 40. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. *N Engl J Med.* 1981;305:63–7. [PubMed: 6264292]
 41. Matthes-Martin S, Feuchtinger T, Shaw PJ, Engelhard D, Hirsch HH, Cordonnier C, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). *Transpl Infect Dis.* 2012;14:555–63. [PubMed: 23146063]
 42. Green W, Rao PK, Harocopos GJ. Extramedullary Relapse of Acute Myelogenous Leukemia Presenting as a Large Serous Retinal Detachment. *Ocul Oncol Pathol.* 2017;3:95–100. [PubMed: 28868277]
 43. Matsuo T, Tanaka T, Ichimura K, Meguri Y. Intraocular Relapse with Hypopyon and Retinal Infiltrates after Chemotherapy and Peripheral Blood Stem Cell Transplantation for Extranodal NK/T-Cell Lymphoma. *J Clin Exp Hematop.* 2015;55:157–61. [PubMed: 26763364]
 44. Rothova A, Ooijman F, Kerkhoff F, Van Der Lelij A, Lokhorst HM. Uveitis masquerade syndromes. *Ophthalmology.* 2001;108:386–99. [PubMed: 11158819]
 45. Cohen VM, Dinakaran S, Parsons MA, Rennie IG. Transvitreal fine needle aspiration biopsy: the influence of intraocular lesion size on diagnostic biopsy result. *Eye (Lond).* 2001;15:143–7. [PubMed: 11339578]
 46. Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. *Br J Haematol.* 2004;126:202–8. [PubMed: 15238140]
 47. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. *Ophthalmology.* 2002;109:1709–16. [PubMed: 12208721]
 48. Wiegel T, Bottke D, Kreusel KM, Schmidt S, Bornfeld N, Foerster MH, et al. External beam radiotherapy of choroidal metastases—final results of a prospective study of the German Cancer Society (ARO 95-08). *Radiother Oncol.* 2002;64:13–8. [PubMed: 12208569]
 49. Kaliki S, Shields CL, Al-Dahmash SA, Mashayekhi A, Shields JA. Photodynamic therapy for choroidal metastasis in 8 cases. *Ophthalmology.* 2012;119:1218–22. [PubMed: 22386261]
 50. Gratwohl A, Gloor B, Hahn H, Speck B. Retinal cotton-wool patches in bone-marrow-transplant recipients. *N Engl J Med.* 1983;308:1101. [PubMed: 6339934]
 51. Hirst LW, Jabs DA, Tutschka PJ, Green WR, Santos GW. The eye in bone marrow transplantation. I. Clinical study. *Arch Ophthalmol.* 1983;101:580–4. [PubMed: 6340648]
 52. Bernauer W, Gratwohl A, Keller A, Daicker B. Microvasculopathy in the ocular fundus after bone marrow transplantation. *Ann Intern Med.* 1991;115:925–30. [PubMed: 1952488]
 53. Johnson DW, Cagnoni PJ, Schossau TM, Stemmer SM, Grayeb DE, Baron AE, et al. Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support. *Bone Marrow Transplant.* 1999;24:785–92. [PubMed: 10516683]
 54. Bylsma GW, Hall AJ, Szer J, West R. Atypical retinal microvasculopathy after bone marrow transplantation. *Clin Exp Ophthalmol.* 2001;29:225–9. [PubMed: 11545420]
 55. Westeneng AC, Hettinga Y, Lokhorst H, Verdonck L, van Dorp S, Rothova A. Ocular graft-versus-host disease after allogeneic stem cell transplantation. *Cornea.* 2010;29:758–63. [PubMed: 20489577]
 56. Ivanir Y, Shimoni A, Ezra-Nimni O, Barequet IS. Prevalence of dry eye syndrome after allogeneic hematopoietic stem cell transplantation. *Cornea.* 2013;32:e97–101. [PubMed: 23187163]
 57. Aissopou EK, Papathanassiou M, Nasothimiou EG, Konstantonis GD, Tentolouris N, Theodossiadis PG, et al. The Keith-Wagener-Barker and Mitchell-Wong grading systems for hypertensive retinopathy: association with target organ damage in individuals below 55 years. *J Hypertens.* 2015;33:2303–9. [PubMed: 26335430]

58. Kaushik M, Pulido JS, Schild SE, Stafford S. Risk of radiation retinopathy in patients with orbital and ocular lymphoma. *Int J Radiat Oncol Biol Phys.* 2012;84:1145–50. [PubMed: 22592046]
59. Cooper AE, Cho JH, Menges S, Masood S, Xie J, Yang J, et al. Immunosuppressive Treatment Can Alter Visual Performance in the Royal College of Surgeons Rat. *J Ocul Pharmacol Ther.* 2016;32:296–303. [PubMed: 27008099]
60. Avery R, Jabs DA, Wingard JR, Vogelsang G, Saral R, Santos G. Optic disc edema after bone marrow transplantation. Possible role of cyclosporine toxicity. *Ophthalmology.* 1991;98:1294–301. [PubMed: 1923369]
61. Lopez PF, Sternberg P Jr., Dabbs CK, Vogler WR, Crocker I, Kalin NS. Bone marrow transplant retinopathy. *Am J Ophthalmol.* 1991;112:635–46. [PubMed: 1957898]
62. Pahl DA, Green NS, Bhatia M, Lee MT, Chang JS, Licursi M, et al. Optical Coherence Tomography Angiography and Ultra-widefield Fluorescein Angiography for Early Detection of Adolescent Sickle Retinopathy. *Am J Ophthalmol.* 2017;183:91–8. [PubMed: 28860042]
63. Joltikov KA, de Castro VM, Davila JR, Anand R, Khan SM, Farbman N, et al. Multidimensional Functional and Structural Evaluation Reveals Neuroretinal Impairment in Early Diabetic Retinopathy. *Invest Ophthalmol Vis Sci.* 2017;58:BIO277–BIO90. [PubMed: 28973314]
64. Hillier RJ, Ojaimi E, Wong DT, Mak MYK, Berger AR, Kohly RP, et al. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. *JAMA Ophthalmol.* 2018;136:382–8. [PubMed: 29522144]
65. Baker KS, Ness KK, Weisdorf D, Francisco L, Sun CL, Forman S, et al. Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. *Leukemia.* 2010;24:2039–47. [PubMed: 20861916]
66. Saboo US, Amparo F, Shikari H, Dana R. Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease. *Graefes Arch Clin Exp Ophthalmol.* 2016;254:923–8. [PubMed: 26968719]
67. Takeda A, Shigematsu N, Suzuki S, Fujii M, Kawata T, Kawaguchi O, et al. Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity. *Int J Radiat Oncol Biol Phys.* 1999;44:599–605. [PubMed: 10348290]
68. Tatematsu Y, Ogawa Y, Abe T, Kamoi M, Uchino M, Saijo-Ban Y, et al. Grading criteria for chronic ocular graft-versus-host disease: comparing the NIH eye score, Japanese dry eye score, and DEWS 2007 score. *Sci Rep.* 2014;4:6680. [PubMed: 25338290]
69. Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. *Drugs Aging.* 1999;15:439–50. [PubMed: 10641955]
70. Kwok AK, Lam DS, Ng JS, Fan DS, Chew SJ, Tso MO. Ocular-hypertensive response to topical steroids in children. *Ophthalmology.* 1997;104:2112–6. [PubMed: 9400772]
71. Katz G, Dubiner H, Samples J, Vold S, Sall K. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. *JAMA Ophthalmol.* 2013;131:724–30. [PubMed: 23579344]
72. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S, Low-Pressure Glaucoma Study G. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. *Am J Ophthalmol.* 2011;151:671–81. [PubMed: 21257146]
73. Im L, Allingham RR, Singh I, Stinnett S, Fekrat S. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. *J Glaucoma.* 2008;17:128–32. [PubMed: 18344759]
74. Rubin B, Taglienti A, Rothman RF, Marcus CH, Serle JB. The effect of selective laser trabeculoplasty on intraocular pressure in patients with intravitreal steroid-induced elevated intraocular pressure. *J Glaucoma.* 2008;17:287–92. [PubMed: 18552614]
75. Zhou JQ, Xu L, Wang S, Wang YX, You QS, Tu Y, et al. The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. *Ophthalmology.* 2013;120:803–8. [PubMed: 23352194]
76. Yoo YS, Na KS, Shin JA, Park YH, Lee JW. Posterior Eye Segment Complications Related to Allogeneic Hematopoietic Stem Cell Transplantation. *Retina.* 2017;37:135–43. [PubMed: 27380428]

77. Campa C, Alivernini G, Bolletta E, Parodi MB, Perri P. Anti-VEGF Therapy for Retinal Vein Occlusions. *Curr Drug Targets*. 2016;17:328–36. [PubMed: 26073857]
78. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. *Ophthalmology*. 2012;119:2587–91. [PubMed: 22902212]
79. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. *Ophthalmology*. 2012;119:802–9. [PubMed: 22301066]
80. Haller JA, Bandello F, Belfort R Jr., Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology*. 2011;118:2453–60. [PubMed: 21764136]
81. Pikkel YY, Sharabi-Nov A, Beiran I, Pikkel J. Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion. *Int J Ophthalmol*. 2016;9:431–3. [PubMed: 27158615]
82. Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. *Transpl Infect Dis*. 2008;10:13–8. [PubMed: 17511815]
83. Peng KL, Chen SJ, Lin PY, Hsu WM, Yang MH, Tzeng CH, et al. Exudative bullous retinal detachment after peripheral blood stem cell transplantation. *Eye (Lond)*. 2005;19:603–6. [PubMed: 15332110]
84. Wiznia RA, Rose A, Levy AL. Occlusive microvascular retinopathy with optic disc and retinal neovascularization in acute lymphocytic leukemia. *Retina*. 1994;14:253–5. [PubMed: 7973121]
85. Alloin AL, Barlogis V, Auquier P, Contet A, Poiree M, Demeocq F, et al. Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study. *Br J Haematol*. 2014;164:94–100. [PubMed: 24116693]
86. Abud TB, Amparo F, Saboo US, Di Zazzo A, Dohlman TH, Ciolino JB, et al. A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease. *Ophthalmology*. 2016;123:1449–57. [PubMed: 27086024]
87. Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. *Cornea*. 2009;28:1091–6. [PubMed: 19770713]
88. Dietrich-Ntoukas T, Cursiefen C, Westekemper H, Eberwein P, Reinhard T, Bertz H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. *Cornea*. 2012;31:299–310. [PubMed: 22157574]
89. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. *Drugs*. 2004;64:1997–2020. [PubMed: 15341494]
90. Slattery A, Liebelt E, Gaines LA. Common ocular effects reported to a poison control center after systemic absorption of drugs in therapeutic and toxic doses. *Curr Opin Ophthalmol*. 2014;25:519–23. [PubMed: 25226509]
91. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications : recognition and management. *Drugs*. 2007;67:75–93. [PubMed: 17209665]
92. Jaanus SD. Ocular side effects of selected systemic drugs. *Optom Clin*. 1992;2:73–96. [PubMed: 1363080]
93. Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. *CNS Drugs*. 2010;24:501–26. [PubMed: 20443647]
94. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. *Drug Saf*. 2008;31:127–41. [PubMed: 18217789]
95. Laties AM, Fraunfelder FT. Ocular safety of Viagra, (sildenafil citrate). *Trans Am Ophthalmol Soc*. 1999;97:115–25; discussion 25-8. [PubMed: 10703120]
96. Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. *Drug Saf*. 2002;25:233–50. [PubMed: 11994027]
97. Mynarek M, Ganzenmueller T, Mueller-Heine A, Mielke C, Gonnermann A, Beier R, et al. Patient, virus, and treatment-related risk factors in pediatric adenovirus infection after stem cell

transplantation: results of a routine monitoring program. *Biol Blood Marrow Transplant.* 2014;20:250–6. [PubMed: 24269896]

98. Lass JH, Lazarus HM, Reed MD, Herzig RH. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. *Am J Ophthalmol.* 1982;94:617–21. [PubMed: 6756155]
99. Fraunfelder FW, Solomon J, Druker BJ, Esmali B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). *J Ocul Pharmacol Ther.* 2003;19:371–5. [PubMed: 12964961]

Highlights

- Non-GVHD ocular complications are reviewed by expert transplant physicians and ophthalmologists.
- Cataracts, ischemic microvascular retinopathy and CMV retinitis are relatively common.
- A variety of medications can cause ocular toxicities after HCT.
- Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT.
- Better preventive strategies and treatments remain to be investigated.




Figure 1.
Structures of the eye

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2.
Ocular infections after allogeneic hematopoietic cell transplantation

Table 1.

Evidence-based rating system used in this review

Category Definition	
Strength of the Recommendation:	
A	Should always be offered.
B	Should generally be offered.
C	Evidence for efficacy is insufficient to support a recommendation for or against, or evidence for efficacy might not outweigh adverse consequences, or cost of the approach. Optional.
D	Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be offered.
E	Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered.
Quality of Evidence Supporting the Recommendation:	
I	Evidence from at least one properly randomized, controlled trial.
II	Evidence for at least one well-designed clinical trial without randomization, from cohort or case-controlled analytic studies (preferable from more than one center) or from multiple time-series or dramatic results from uncontrolled experiments.
III	Evidence from opinions of respected authorities based on clinical experience, descriptive.

Table 2.

Involved structures, symptoms and diagnostic tests of ocular infections following HCT

Organism	Involved structures	Symptoms and clinical findings	Diagnostic tests
Bacteria ²¹ <i>Staphylococci</i> , <i>Haemophilus</i> , <i>Streptococci</i> , <i>Pseudomonas</i> , and others	Lids, conjunctiva, cornea, intraocular	Pain or irritation, erythema, discharge, photophobia, impaired vision	Conjunctival culture, culture of corneal scrapings or vitreal fluid
Fungi ²¹	Cornea, intraocular	Pain, erythema, photophobia, excessive tearing or discharge, blurred vision, vision loss	Corneal infiltrates with feathery edges, culture of corneal scrapings or vitreal fluid
Toxoplasma ^{23, 24}	Retina	Pain, photophobia, scotoma, blurred vision, vision loss	Raised, yellow/white, cottony retinal lesions in a non-vascular distribution and vitreal inflammation, serum PCR or serology, PCR of aqueous humor, vitreal fluid and tissue
Virus			
Cytomegalovirus ²⁵⁻²⁸	Retina	May be asymptomatic early, visual loss, floaters, progressive visual loss	Dilated pupil examination showing creamcolored lesions with hemorrhage and perivascular cuffing of retinal vessels, PCR of vitreous fluid
Herpes simplex virus ²⁹ Varicella zoster virus ^{30, 31}	Conjunctiva, cornea	May be asymptomatic, periorbital pain or rash, conjunctival erythema, blurred vision, vision loss	Swelling and cloudiness of cornea on ophthalmologic exam, PCR, DFA from base of skin lesion scrapings, viral culture
Adenovirus ^{32, 41, 97}	Conjunctiva, cornea	Erythema, chemosis, discharge	Culture, PCR

PCR, polymerase chain reaction; DFA, direct fluorescent assay.

Table 3.

Medications with ocular toxicities

Drug	Ocular toxicity	Frequency	Management and prevention recommendation	Strength
Cytosine arabinoside	Keratoconjunctivitis ⁹⁸	Common	Prophylactic glucocorticoid eye drops, ⁹⁸ 2-deoxycytidine eye drops applied prior to therapy ⁹⁸	A-II
	Ocular pain, tearing, foreign body sensation, photophobia, epiphora, blurred vision with evidence of bilateral conjunctival hyperemia and fine corneal punctate opacities ⁹⁸	Occasional	Eye washing with physiologic saline, 0.1% sodium betamethasone eye drops applied prior to therapy	B-III
Imatinib	Peri-orbital edema, sometimes leading to visual obstruction ⁹⁹	Common	Warm compress	A-III
Corticosteroids (systemic)	Cataracts, ^{13, 14, 85} increased IOP, glaucoma ^{66, 68, 69}	Common	Limit use	A-III
			Screening for cataracts and glaucoma	C-III
Corticosteroids (topical)	Increased IOP, glaucomatous optic atrophy, visual field defects, cataracts, infectious keratitis	Occasional to rare	Monitor IOP within 1 month of initiating treatment, restrict extended use of high potency steroids	A-III
			Regular screening for cataracts, surgery as needed ¹⁸	B-III
			Discontinue steroids, ⁶⁶ topical aqueous humor suppressants, ^{71, 72} trabeculectomy ⁷³	A-I
Cyclosporine (systemic)	Microvascular retinopathy ⁶⁰	Rare	Improve with drug discontinuation ⁶⁰	A-II
Cyclosporine (topical)	Redness, stinging, burning	Occasional	Lubricating drops, ⁸⁸ chill bottle ⁸⁷ before instilling cyclosporine	A-II
Tacrolimus (topical)	Burning sensation	Common	Symptoms typically improve in 1 month after drug discontinuation. ⁸⁶	A-II
Phenothiazines (chlorpromazine, thioridazine)	Abnormal pigmentation of the eyelids, interpalpebral conjunctiva and cornea with long-term use ⁹⁴	Common	Improve with drug discontinuation	B-III
	Decreased accommodation and deposits in the lens	Common	Topical cholinergic agent	B-III
Tricyclic antidepressants (amitriptyline)	Mydriasis, cycloplegia, blurred vision, presbyopia, mild and transient visual disturbances ⁹³	Common	Improve with time as tolerance develops. ⁹³ Topical cholinergic agents (bethanechol or pilocarpine)	B-II
	Decreased lacrimation, dry eyes, glaucoma attacks (anticholinergic)	Rare to common	Artificial tears, avoid in patients with narrow angles ⁹³	B-II
Selective serotonin reuptake inhibitors (sertraline, paroxetine, fluoxetine, citalopram)	Mydriasis, reduced accommodation, increased	Common	Improve with drug discontinuation	B-III

Drug	Ocular toxicity	Frequency	Management and prevention recommendation	Strength
	IOP, glaucoma, ⁹³ blurred vision			
Antihistamines (chlorpheniramine, meclizine, promethazine, diphenhydramine)	Mydriasis (anticholinergic) ⁹⁰ , dry eyes, decreased accommodation	Common	Transient, reversible	B-III
	Angle closure glaucoma (anticholinergic)	Rare	Avoid in patients with angle closure glaucoma	B-III
Scopolamine patch	Anisocoria, mydriasis, dry eyes ⁹²	Common	Avoid rubbing eyes with fingers after application of the patch ⁹²	A-II
Voriconazole	Blurred vision, changes in visual acuity, color perception, photophobia, visual hallucinations ⁸⁹	Common	Consider alternative drugs	A-III
Erectile dysfunction drugs (e.g., sildenafil)	Blue vision ⁹⁵	Common	Improve with drug discontinuation	B-II
Non-steroidal anti-inflammatory drugs (topical)	Redness, stinging, corneal epithelial toxicity, stromal necrosis (corneal melts) especially in dry eyes	Occasional	Limit use for dry eye or GVHD, drug discontinuation ⁹⁶	B-II

IOP, intraocular pressure; GVHD, graft-versus-host disease.

Table 4.

Incidence, risk factor, screening and prevention recommendations of non-GVHD ocular complications after HCT

Complication	Incidence	Risk factor	Prevention and screening recommendation (strength)
Cataracts	11%-100% in adults, ^{5, 6} 4%-76% in children ^{7, 8}	TBI (particularly single dose or dose rate >0.04 Gy/min), ^{9, 10} corticosteroids, ¹³⁻¹⁵ allogeneic HCT ¹⁰	Hyper-fractionated TBI instead of single-dose TBI ⁹ (A-I), non-TBI conditioning ¹² (B-II), lens shielding ¹¹ (C-II)
Bacterial infection	<2% ²¹	Neutropenia, ²¹ impaired humoral immunity ²¹	By clinical presentation (A-II)
Fungal infection	<2% ^{21, 22}	Fungemia ³³ , immunosuppression ³³	By clinical presentation or fungemia ³³ (A-III)
Toxoplasma infection	0.3-0.5% ^{23, 24}	Pre-HCT infection, ²³ impaired cellular immunity ²³	Pre-HCT screening examination for retina scar and serologic testing ³⁷ (B-III), by clinical presentation
Viral infection			
Cytomegalovirus (CMV)	Retinitis <1%-5% in all HCT patients, 5%-23% in patients with CMV viremia ²⁵⁻²⁸	Positive serostatus, ²⁵ viremia pre-HCT, ²⁷ reactivation by day+100, ²⁵ high peak DNA levels, ²⁶ delayed lymphocyte engraftment, ²⁵ chronic GVHD, ^{25, 27} HLA mismatching, ^{26, 27} unrelated donor ²⁶	Screening fundoscopic examination in patients at risk every 6-8 weeks (B-III)
Herpes simplex virus (HSV), Varicella zoster virus (VZV)	Rare, ^{29, 31} 2% of VZV infection ³⁰	Extensive chronic GVHD ³⁰	By clinical presentation (A-III), prophylactic acyclovir ⁴⁰ (A-I)
Adenovirus	Rare	No data	PCR surveillance for systemic reactivation in high risk patients (B-III)
Involvement with malignancy	Rare	No data	Evaluation of ocular involvement in patients with relapsed primary disease and ocular symptoms ^{42, 43} (C-III), and in asymptomatic high-risk patients (previous ocular involvement, new malignancy involving central nervous system) ⁴⁴ (C-III)
Ischemic microvascular retinopathy	0-10% ^{21, 22, 51-56}	TBI, ^{22, 52, 54} cyclosporine, ^{22, 52} conditioning regimens including busulfan or carmustine ^{53, 54}	Avoid radiation to ocular areas, monitor levels of calcineurin inhibitors (B-III)
Glaucoma	0.4-1.7% ^{65, 66}	Irradiation, ⁶⁷ topical or systemic corticosteroids ^{66, 68, 69}	Monitor intraocular pressure in patients with risk factors (A-II)
Central retinal vein occlusion	Rare	Hypertension, hyperlipidemia, diabetes mellitus, hypercoagulability, hyperviscosity	Fundoscopic testing if visual acuity impairment (A-III)
Retinal hemorrhage	3.2% ⁷⁶	Cytopenia, particularly thrombocytopenia	Fundoscopic testing if visual acuity impairment (A-III)
Retinal detachment	<1%, ^{27, 76}	CMV retinitis ⁷⁶	Fundoscopic testing if visual acuity impairment (A-III)

TBI, total body irradiation; HCT, hematopoietic cell transplantation; GVHD, graft-versus-host disease.

Table 5.

Treatment recommendations of non-GVHD ocular complications after HCT

Complication	Treatment recommendation	Strength
Cataracts	Surgery ¹⁷	A-II
Bacterial infection	Antibiotic eye drops, ³⁴ oral or intravenous antibiotic agents, intravitreal injections	A-I
Fungal infection	Antifungal eye drops, ³⁶ oral or intravenous antifungal agents, intravitreal injections ³⁵	A-I
Toxoplasma infection	Trimethoprim-sulfamethoxazole-pyrimethamine, clindamycin, atovaquone, azithromycin ³⁸	A-I
Viral infection		
Cytomegalovirus	Intravenous ganciclovir, oral valganciclovir, intravenous foscarnet ²⁸	A-II
	Intravitreal ganciclovir or foscarnet for resistant infections ²⁸	B-II
	Virus-specific T-cell infusion ³⁹	C-II
Herpes simplex virus	Oral acyclovir/valacyclovir/famciclovir, intravenous acyclovir	A-II
Varicella zoster virus	Oral acyclovir/valacyclovir/famciclovir, intravenous acyclovir for ophthalmic	A-II
Adenovirus	Decrease immunosuppression, intravenous cidofovir ⁴¹	A-II
Involvement with malignancy	Intravitreal chemotherapy, radiation therapy, photodynamic laser therapy, disease-specific interventions based on site and histology of neoplasm ⁴⁷⁻⁴⁹	C-III
Ischemic microvascular retinopathy	Reduction or withdrawal of calcineurin inhibitors, ⁶⁰ treatment for hypertension, GVHD and transplant-associated microangiopathy	B-III
Glaucoma	Discontinue steroids, ⁶⁶ topical aqueous humor suppressants, ^{71, 72} trabeculectomy ⁷³	A-I
Central retinal vein occlusion	Intravitreal anti-VEGF injections ^{78, 79}	A-I
	Intravitreal glucocorticoids ⁸⁰	B-I
	Macular grid and panretinal laser photocoagulation ⁸¹	C-II
Retinal hemorrhage	Maintain the platelet count over 50,000/ μ l	B-III
Retinal detachment	Photocoagulation, cryotherapy and surgical techniques	B-III

VEGF, vascular endothelial growth factor.